Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

360
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
360
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulatory T cells in cancer anti-PD-(L)1 therapy.

Human cell·2025
Same author

Selective targeting or reprogramming of intra-tumoral Tregs.

Medical oncology (Northwood, London, England)·2024
Same author

An Update of Extracellular Vesicle Involvement in Different Steps of Cancer Metastasis and Targeting Strategies.

Current medicinal chemistry·2024
Same author

Extracellular vesicle-based drug delivery in cancer immunotherapy.

Drug delivery and translational research·2023
Same author

The impact of hypoxia on extracellular vesicle secretome profile of cancer.

Medical oncology (Northwood, London, England)·2023
Same author

Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.

Journal of cellular and molecular medicine·2023
Same journal

The preventable burden of tobacco-attributable cancer incidence in Catalonia (Spain) in 2024: a Bayesian approach.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Neoadjuvant metformin on clinical and pathological response in non-diabetic patients with non-metastatic breast cancer: an updated systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K

Microbiota interaction with Tregs: a target for colitis.

Keywan Mortezaee1,2

  • 1Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. keywan987@yahoo.com.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|June 26, 2025
PubMed
Summary
This summary is machine-generated.

The gut microbiome influences regulatory T cells (Tregs) to maintain immune balance and prevent bowel inflammation. Harnessing this microbiome-Treg interaction, particularly through fecal microbial transplantation (FMT), offers a promising therapeutic strategy for colitis.

Keywords:
ColitisFecal microbial transplantation (FMT)MicrobiotaRegulatory T cell (Treg)Short-chain fatty acid (SCFA)

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Related Experiment Videos

Last Updated: Sep 8, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Area of Science:

  • Immunology
  • Microbiology
  • Gastroenterology

Background:

  • Gut microbiota and regulatory T cells (Tregs) are crucial for immune homeostasis and preventing inflammation.
  • Tregs possess immunosuppressive activity, vital for maintaining gut health and limiting inflammatory responses.
  • Dysbiosis and reduced Treg function are implicated in inflammatory bowel diseases like colitis.

Purpose of the Study:

  • To review the impact of the gut microbiome on Tregs in the context of bowel inflammation.
  • To explore therapeutic strategies involving microbiome-Treg interactions for managing colitis.
  • To understand the role of this interplay in cancer immunotherapy-induced colitis.

Main Methods:

  • Literature review focusing on microbiome-Treg interactions in gut inflammation.
  • Analysis of microbial metabolites, such as short-chain fatty acids (SCFAs), and their effect on Treg differentiation.
  • Examination of fecal microbial transplantation (FMT) as a therapeutic approach for colitis.

Main Results:

  • Microbial SCFAs promote Treg generation and maintenance, counteracting bowel inflammation.
  • Treg induction influences gut microbiota composition, enhancing host protection.
  • Fecal microbial transplantation (FMT) can restore Treg populations and gut barrier function, ameliorating colitis.

Conclusions:

  • Modulating Treg-microbiota interactions, including Treg reprogramming and FMT, presents a viable therapeutic avenue for colitis.
  • FMT can re-establish immune balance by promoting Tregs and beneficial microbes, even in cancer patients undergoing immunotherapy.
  • Understanding the Treg-microbiome axis is key to developing novel treatments for inflammatory conditions.